TheProductLawyers.com reports on Xarelto and the ongoing controversy surrounding the drug. When Xarelto was approved by the U.S. Food and Drug Administration (FDA) in 2011, it was a widely popular blood-thinning treatment. The blood thinner drug is now, however, the focus of investigations that are looking into its initial approval stages and whether integral data obtained during clinical trials was omitted when information was sent to reputable medical journals.
In addition to these latest allegations related to the clinical trials, Xarelto is also currently at the heart of over 3,000 lawsuits, with 2,800 of these being federally-filed lawsuits consolidated by the U.S. Judicial Panel on Multidistrict Litigation (JPML) to form MDL 2592 under the oversight of a Federal Judge in Eastern Louisiana. In Philadelphia, PA, the Court of Common Pleas has consolidated another 600 or more cases into a mass tort program. There is an expectation that the numbers of cases in both of these groups will increase in the future.
Plaintiffs in these cases are alleging that the manufacturers of the drug, Janssen Pharmaceuticals, a subsidiary company of the Johnson and Johnson Corporation, and Bayer AG, purposefully and intentionally misled the public about the drug in its public media campaign to promote its sale. The plaintiffs also claim that Xarelto is dangerous in that it can cause instances of severe and sometimes fatal uncontrollable bleeding.
Given the swirling controversy over Xarelto and other blood-thinning drugs, it is likely that many people will be looking to alternative therapies such as those promoted by Vascular PRN. Vascular PRN distributes a pneumatic compression device that uses alternating compression to improve blood flow and prevent clots in those patients recovering from surgery or those who are immobile such as nursing home patients. Vascular PRN offers a blood clot therapy without the risks such as those that exist with anticoagulants.
The attorneys of Banville Law, the firm behind TheProductLawyers.com, are offering complimentary consultations to anyone who suffered injury or hospitalization after a bleed while on Xarelto. For more information about this release or the Xarelto litigation call 888-478-9711.
TheProductLawyers.com is a resource website sponsored by Banville Law to provide information on pending lawsuits against defective products, drugs and medical devices.
165 West End Ave #1h,
New York, NY 10023
November 30, 2016 – Research Indicates New Form Of Treating Ovarian Cancer As Talcum Powder Lawsuit Numbers Climb
November 30, 2016 – Parties in Talcum Powder Lawsuit In Missouri Exchange Briefings
November 30, 2016 – J&J Requests Disclosure Of Third Party Litigation Financing In Talcum Powder Lawsuit
November 30, 2016 – Delaware Sees 10 New Talcum Powder Lawsuit Filings
November 29, 2016 – Philadelphia Talcum Powder Lawsuit Filed Against Johnson & Johnson To Proceed
November 29, 2016 – Pennsboro Woman Files Talcum Powder Lawsuit On Behalf Of Her Deceased Mother
November 29, 2016 – Bioimaging Helps Early Detection Of Ovarian Cancer As Talcum Powder Lawsuit Filings Continue
November 28, 2016 – FDA Follow-Up: How Officials Have Responded To The Influx Of Talcum Powder Lawsuit Filings
November 28, 2016 – Talc Uses: A Look At The Product At The Center Of Talcum Powder Lawsuit Filings
November 28, 2016 – More Women Encouraged To File A Talcum Powder Lawsuit After Verdicts